Physicians at the University of Illinois Hospital & Health Sciences System have cured 12 adult patients of sickle cell disease using a unique procedure for stem cell transplantation from healthy, tissue-matched siblings.
The transplants were the first to be performed outside of the National Institutes of Health campus in Maryland, where the procedure was developed. Physicians there have treated 30 patients, with an 87 percent success rate. The results of the phase I/II clinical trial at UI Health, in which 92 percent of treated patients were cured, are published online in the journal Biology of Blood & Marrow Transplantation.
The new technique eliminates the need for chemotherapy to prepare the patient to receive the transplanted cells and offers the prospect of cure for tens of thousands of adults suffering from sickle cell disease.
About 90 percent of the approximately 450 patients who have received stem cell transplants for sickle cell disease have been children. Chemotherapy has been considered too risky for adult patients, who are often more weakened than children by the disease.
“Adults with sickle cell disease are now living on average until about age 50 with blood transfusions and drugs to help with pain crises, but their quality of life can be very low,” says Dr. Damiano Rondelli, chief of hematology/oncology and director of the blood and marrow transplant program at UI Health, and corresponding author on the paper.
“Now, with this chemotherapy-free transplant, we are curing adults with sickle cell disease, and we see that their quality of life improves vastly within just one month of the transplant,” said Rondelli, who is also the Michael Reese Professor of Hematology in the UIC College of Medicine. “They are able to go back to school, go back to work, and can experience life without pain.”
Sickle cell disease is inherited. It primarily affects people of African descent, including about one in every 500 African Americans born in the U.S. The defect causes the oxygen-carrying red blood cells to be crescent shaped, like a sickle. The misshapen cells deliver less oxygen to the body’s tissues, causing severe pain and eventually stroke or organ damage.
Doctors have known for some time that bone marrow transplantation from a healthy donor can cure sickle cell disease. But few adults were transplanted because high-dose chemotherapy was needed to kill off the patients’ own blood-forming cells — and their entire immune system, to prevent rejection of the transplanted cells, leaving patients open to infection.
In the new procedure, patients receive immunosuppressive drugs just before the transplant, along with a very low dose of total body irradiation — a treatment much less harsh and with fewer potentially serious side effects than chemotherapy.
Next, donor cells from a healthy and tissue-matched sibling are transfused into the patient. Stem cells from the donor produce healthy new blood cells in the patient, eventually in sufficient quantity to eliminate symptoms. In many cases, sickle cells can no longer be detected. Patients must continue to take immunosuppressant drugs for at least a year.
In the reported trial, the researchers transplanted 13 patients, 17 to 40 years of age, with a stem cell preparation from the blood of a tissue-matched sibling. Healthy sibling donor-candidates and patients were tested for human leukocyte antigen, a set of markers found on cells in the body. Ten of these HLA markers must match between the donor and the recipient for the transplant to have the best chance of evading rejection.
In a further advance of the NIH procedure, physicians at UI Health successfully transplanted two patients with cells from siblings who matched for HLA but had a different blood type.
In all 13 patients, the transplanted cells successfully took up residence in the marrow and produced healthy red blood cells. One patient who failed to follow the post-transplant therapy regimen reverted to the original sickle cell condition.
None of the patients experienced graft-versus-host disease, a condition where immune cells originating from the donor attack the recipient’s body.
One year after transplantation, the 12 successfully transplanted patients had normal hemoglobin concentrations in their blood and better cardiopulmonary function. They reported less pain and improved health and vitality.
Four of the patients were able to stop post-transplantation immunotherapy without transplant rejection or other complications.
The Latest on: Sickle cell disease
via Google News
The Latest on: Sickle cell disease
- Gene-Edited 'Supercells' Make Progress In Fight Against Sickle Cell Diseaseon November 19, 2019 at 5:08 am
Doctors are reporting the first evidence that genetically edited cells could offer a safe way to treat sickle cell disease, a devastating, incurable disorder that afflicts millions of people around ...
- Promising new sickle cell disease medicine wins FDA approvalon November 18, 2019 at 2:08 pm
This undated image provided by Novartis shows bottles of Novartis’s Adakveo. U.S. regulators have approved the new sickle cell disease medicine that can prevent extremely painful, dangerous “crises” ...
- FDA Approves Crizanlizumab, A New Drug For Sickle Cell Diseaseon November 18, 2019 at 10:14 am
It isn’t the easiest drug name to pronounce, but crizanlizumab-tmca will be the first ever available targeted therapy for sickle cell disease. On Friday, the U.S. Food and Drug Administration (FDA) ...
- Sickle Cell Disease Therapeutics Market 2019-2026 | Focuses on the Global Key Manufacturers, Competition Landscape and SWOT Analysison November 18, 2019 at 7:46 am
Nov 18, 2019 (Global QYResearch via COMTEX) -- Ameco Research in its report titled, "Sickle Cell Disease Therapeutics Market Analysis 2019 – Projections Report 2026," offers comprehensive insights and ...
- Sickle Cell Disease Treatment Market Application, Manufacturer, Sales, Segmentation and Forecast 2019 to 2026on November 18, 2019 at 7:41 am
Nov 18, 2019 (Global QYResearch via COMTEX) -- Ameco Research in its report titled, "Sickle Cell Disease Treatment Market Analysis 2019 – Projections Report 2026," offers comprehensive insights and ...
- Novartis Receives FDA Nod for Adakveo in Sickle Cell Diseaseon November 18, 2019 at 6:36 am
Novartis NVS announced that the FDA has approved Adakveo (crizanlizumab) to reduce the frequency of vaso-occlusive crises (VOCs) or pain crises in adult and pediatric patients aged 16 years or above ...
- Novartis eyes $1B sales with FDA nod for targeted sickle cell disease drug Adakveoon November 16, 2019 at 3:16 am
Another candidate for Novartis' future blockbuster club is here. Friday, the Swiss drugmaker won FDA approval for Adakveo, the first targeted therapy to prevent the painful vaso-occlusive crises (VOCs ...
- FDA approves Novartis drug to treat pain crises in sickle cell diseaseon November 15, 2019 at 5:27 pm
Novartis announced late Friday that the Food and Drug Administration has approved Adakveo — formerly called SEG101 — to reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in adult ...
- FDA approves first targeted therapy to treat patients with painful complication of sickle cell diseaseon November 15, 2019 at 4:01 pm
SILVER SPRING, Md., Nov. 15, 2019 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a ...
- U.S. approves new drug to manage sickle cell disease, costs $85,000 to $113,000on November 15, 2019 at 1:59 pm
U.S. regulators on Friday approved a new medicine that can help reduce extremely painful sickle cell disease flare-ups. The Food and Drug Administration approved Novartis AG’s Adakveo for patients 16 ...
via Bing News